ANAB Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
25.6M
-76.4%
108.2M
+41.8%
76.3M
+242.8%
22.3M
-19.8%
27.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
25.6M
-76.4%
108.2M
+41.8%
76.3M
+242.8%
22.3M
-19.8%
27.8M
Operating Expenses
60.2M
+45.6%
41.3M
-0.6%
41.6M
-14.1%
48.4M
-12.4%
55.3M
R&D
34.0M
+33.0%
25.6M
-18.6%
31.4M
-17.0%
37.8M
-8.1%
41.2M
SG&A
26.2M
+66.0%
15.8M
+54.7%
10.2M
-3.8%
10.6M
-24.9%
14.1M
Operating Income
-34637000
-151.8%
66.9M
+92.8%
34.7M
+232.6%
-26170000
+5.0%
-27539000
EBITDA
-34507000
-151.5%
67.0M
+92.4%
34.8M
+233.9%
-26028000
+5.0%
-27393000
Net Income
-52884000
-206.6%
49.6M
+228.3%
15.1M
+139.1%
-38630000
+1.8%
-39329000
EPS (Basic)
$-1.84
-202.8%
$1.79
+231.5%
$0.54
+140.3%
$-1.34
-4.7%
$-1.28
EPS (Diluted)
$-1.84
-198.4%
$1.87
+259.6%
$0.52
+138.8%
$-1.34
-4.7%
$-1.28
Shares (Diluted)
28.7M
+8.0%
26.6M
-8.5%
29.0M
+0.7%
28.8M
-6.0%
30.6M
AnaptysBio (ANAB) โ€” Financials